Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1989-9-28
|
pubmed:abstractText |
Epstein-Barr virus (EBV) readily immortalizes human peripheral blood lymphocytes (PBL) in vitro. However, during the past several years, we found that PBL from two exceptional EBV-seropositive healthy adult individuals were refractory to immortalization by EBV. We report here a study aimed at learning about the immunobiological features which differentiate these EBV-resistant (R) PBL from others which are susceptible (S) to EBV immortalization. Results of this investigation indicate that: (a) Following EBV infection, R-PBL produced significantly higher amounts of interferon gamma (IFN-gamma) than S-PBL. There were however no differences in regard to interferon alpha production between these two types (R and S) of EBV-infected cultures. (b) R-PBL had a maximal interleukin-2 (IL-2) production by S-PBL occurred at least 48 hr later, i.e., at Day 7. (c) The percentage of non-B cells expressing the IL-2 receptor was also higher in EBV-infected R-PBL than S-PBL. (d) In contrast, expression of IL-2 receptors after EBV infection was higher on B cells from S-PBL than on B cells from R-PBL. Interestingly, no differences were noted in regard to IL-2 receptor expression between R-PBL and S-PBL treated with mitogens (i.e., phytohemagglutinin and pokeweed mitogen). (e) Finally, using anti-IL-2 and anti-IFN-gamma antibodies in EBV-infected R-PBL cultures, we were able to obtain EBV-induced immortalization of these cultures. Taken together, these results suggest that an early IL-2 synthesis and high IFN-gamma production by EBV-infected PBL play an important role against lymphocyte immortalization by EBV.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0008-8749
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
122
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
440-9
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:2548740-Antigen-Antibody Reactions,
pubmed-meshheading:2548740-Antigens, Viral,
pubmed-meshheading:2548740-Cell Division,
pubmed-meshheading:2548740-Cell Transformation, Viral,
pubmed-meshheading:2548740-Cells, Cultured,
pubmed-meshheading:2548740-Herpesvirus 4, Human,
pubmed-meshheading:2548740-Humans,
pubmed-meshheading:2548740-Interferon Type I,
pubmed-meshheading:2548740-Interferon-gamma,
pubmed-meshheading:2548740-Interleukin-2,
pubmed-meshheading:2548740-Lymphocytes,
pubmed-meshheading:2548740-Receptors, Interleukin-2
|
pubmed:year |
1989
|
pubmed:articleTitle |
Differential interleukin-2 and interferon-gamma production by human lymphocyte cultures exceptionally resistant to Epstein-Barr virus immortalization.
|
pubmed:affiliation |
Immunology Research Center, Institut Armand-Frappier, Ville de Laval, Québec, Canada.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|